{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T23:52:47Z","timestamp":1790985167156,"version":"4.1.0"},"reference-count":102,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T00:00:00Z","timestamp":1771027200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T00:00:00Z","timestamp":1771027200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum des Saarlandes und Medizinische Fakult\u00e4t der Universit\u00e4t des Saarlandes"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nutr"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Metabolic dysfunction-associated steatotic liver disease (MASLD) and its subtype, metabolic dysfunction-associated alcohol-related liver disease (MetALD), represent the most prevalent chronic liver diseases worldwide, closely linked to unhealthy dietary patterns. Lifestyle modification is considered first-line treatment, yet the comparative effectiveness of different dietary approaches remains unclear. This systematic review and meta-analysis aimed to evaluate the impact of dietary interventions on liver health biomarkers in individuals with MASLD and MetALD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic database search was conducted for randomised controlled trials (RCTs, 2018\u20132024). Eligible trials assessed dietary interventions in MASLD or MetALD and reported changes in alanine aminotransferase (ALT), liver stiffness, MRI-proton density fat fraction (MRI-PDFF), and controlled attenuation parameter. Data were synthesized using weighted mean differences with fixed or random effects models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Sixty-eight full-text articles were included in the systematic review, of which 24 met the criteria for the meta-analysis. Since no eligible studies were identified in individuals with MetALD, the findings apply solely to people with MASLD. In studies on fasting interventions ALT (MD\u2009=\u2009\u2212\u200912.47 IU\/L; 95% CI \u2212\u200922.03,\u2212\u20092.92;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.01;\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20096) and liver stiffness (MD\u2009=\u2009\u2212\u20090.24\u00a0kPa; 95% CI \u2212\u20090.46, \u2212\u20090.03;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.03;\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20094) were reduced compared to controls. The Mediterranean diet (MedDiet) resulted in significant differences in ALT (MD\u2009=\u2009\u2212\u20092.93 IU\/L; 95% CI \u2212\u20095.68, \u2212\u20090.19;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.04;\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20099), liver stiffness (MD\u2009=\u2009\u2212\u20090.35\u00a0kPa; 95% CI \u2212\u20090.54, \u2212\u20090.16;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.00;\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20094), and MRI-PDFF (MD\u2009=\u2009\u2212\u20091.37%; 95% CI \u2212\u20092.33, \u2212\u20090.40;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.01;\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20095). LCHF\/ketogenic diets (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20096) and Omega-3 fatty acids supplementation (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20094) did not significantly alter ALT.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Fasting and MedDiet showed positive effects on surrogate biomarkers in MASLD. Larger, long-term isocaloric RCTs with standardized outcome reporting are warranted to confirm these findings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00394-025-03870-z","type":"journal-article","created":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T07:23:49Z","timestamp":1771053829000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["The impact of dietary interventions on liver health biomarkers in individuals with metabolic dysfunction-associated steatotic liver disease (MASLD): a systematic literature review and meta-analysis of randomized controlled trials"],"prefix":"10.1007","volume":"65","author":[{"given":"Ute M.","family":"Stern","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gudrun","family":"Wagenpfeil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne N.","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saleh A.","family":"Alqahtani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurice","family":"Michel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4224-4703","authenticated-orcid":false,"given":"J\u00f6rn M.","family":"Schattenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,14]]},"reference":[{"issue":"4","key":"3870_CR1","first-page":"374","volume":"17","author":"European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD)","year":"2024","unstructured":"European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) (2024) European association for the study of obesity (EASO), EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol 17(4):374\u2013444","journal-title":"J Hepatol"},{"issue":"4","key":"3870_CR2","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","volume":"77","author":"ZM Younossi","year":"2023","unstructured":"Younossi ZM et al (2023) The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology 77(4):1335\u20131347","journal-title":"Hepatology"},{"issue":"6","key":"3870_CR3","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1038\/s41575-023-00759-2","volume":"20","author":"DQ Huang","year":"2023","unstructured":"Huang DQ et al (2023) Global epidemiology of cirrhosis\u2014aetiology, trends and predictions. Nat Reviews Gastroenterol Hepatol 20(6):388\u2013398","journal-title":"Nat Reviews Gastroenterol Hepatol"},{"issue":"10319","key":"3870_CR4","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/S0140-6736(21)01701-3","volume":"399","author":"TH Karlsen","year":"2022","unstructured":"Karlsen TH et al (2022) The EASL-Lancet liver commission: protecting the next generation of Europeans against liver disease complications and premature mortality. Lancet 399(10319):61\u2013116","journal-title":"Lancet"},{"issue":"31","key":"3870_CR5","doi-asserted-by":"publisher","first-page":"7006","DOI":"10.3748\/wjg.v22.i31.7006","volume":"22","author":"L Abenavoli","year":"2016","unstructured":"Abenavoli L et al (2016) Metabolic aspects of adult patients with nonalcoholic fatty liver disease. World J Gastroenterol 22(31):7006","journal-title":"World J Gastroenterol"},{"issue":"9453","key":"3870_CR6","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/S0140-6736(04)17663-0","volume":"365","author":"MA Pereira","year":"2005","unstructured":"Pereira MA et al (2005) Fast-food habits, weight gain, and insulin resistance (the CARDIA study): 15-year prospective analysis. Lancet 365(9453):36\u201342","journal-title":"Lancet"},{"issue":"5","key":"3870_CR7","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1038\/ajg.2013.95","volume":"108","author":"WH Oddy","year":"2013","unstructured":"Oddy WH et al (2013) The Western dietary pattern is prospectively associated with nonalcoholic fatty liver disease in adolescence. Official J Am Coll Gastroenterology| ACG 108(5):778\u2013785","journal-title":"Official J Am Coll Gastroenterology| ACG"},{"issue":"5","key":"3870_CR8","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.jhep.2007.06.020","volume":"47","author":"S Zelber-Sagi","year":"2007","unstructured":"Zelber-Sagi S et al (2007) Long term nutritional intake and the risk for non-alcoholic fatty liver disease (NAFLD): a population based study. J Hepatol 47(5):711\u2013717","journal-title":"J Hepatol"},{"issue":"6","key":"3870_CR9","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","volume":"64","author":"European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD)","year":"2016","unstructured":"European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) (2016) European association for the study of obesity (EASO), EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 64(6):1388\u20131402","journal-title":"J Hepatol"},{"key":"3870_CR10","doi-asserted-by":"crossref","unstructured":"Vilar-Gomez E et al (2015) Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology, 149(2): 367\u2009\u2013\u200978.e5; quiz e14-5.","DOI":"10.1053\/j.gastro.2015.04.005"},{"issue":"4","key":"3870_CR11","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1007\/s10620-014-3380-3","volume":"60","author":"LM Glass","year":"2015","unstructured":"Glass LM et al (2015) Total body weight loss of \u2265\u200910% is associated with improved hepatic fibrosis in patients with nonalcoholic steatohepatitis. Dig Dis Sci 60(4):1024\u20131030","journal-title":"Dig Dis Sci"},{"issue":"31","key":"3870_CR12","doi-asserted-by":"publisher","first-page":"E875","DOI":"10.1503\/cmaj.191707","volume":"192","author":"S Wharton","year":"2020","unstructured":"Wharton S et al (2020) Obesity in adults: a clinical practice guideline. CMAJ 192(31):E875\u2013E891","journal-title":"CMAJ"},{"key":"3870_CR13","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71","journal-title":"BMJ"},{"key":"3870_CR14","doi-asserted-by":"crossref","unstructured":"Covidence 22.08.2025; Available from: www.covidence.org","DOI":"10.1080\/15424065.2025.2547027"},{"key":"3870_CR15","doi-asserted-by":"crossref","unstructured":"Sterne JA et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ, 366","DOI":"10.1136\/bmj.l4898"},{"key":"3870_CR16","unstructured":"GRADEpro. GRADEpro GDT: GRADEpro Guideline Development Tool [Software]. (2025) 22.08.2025 ; Available from: www.gradepro.org"},{"issue":"10","key":"3870_CR17","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1111\/apt.17941","volume":"59","author":"A Armandi","year":"2024","unstructured":"Armandi A et al (2024) Short-term reduction of dietary gluten improves metabolic-dysfunction associated steatotic liver disease: a randomised, controlled proof-of-concept study. Aliment Pharmacol Ther 59(10):1212\u20131222","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"3870_CR18","doi-asserted-by":"publisher","first-page":"307","DOI":"10.15171\/apb.2018.036","volume":"8","author":"S Asghari","year":"2018","unstructured":"Asghari S et al (2018) Effects of Pharmacologic dose of Resveratrol supplementation on oxidative\/antioxidative status biomarkers in nonalcoholic fatty liver disease patients: a randomized, double-blind, placebo- controlled trial. Adv Pharm Bull 8(2):307\u2013317","journal-title":"Adv Pharm Bull"},{"key":"3870_CR19","doi-asserted-by":"crossref","unstructured":"Asghari S et al (2022) Effects of calorie restricted diet on oxidative\/antioxidative status biomarkers and serum fibroblast growth factor 21 levels in nonalcoholic fatty liver disease patients: a randomized, controlled clinical trial. Nutrients, 14(12)","DOI":"10.3390\/nu14122509"},{"issue":"3","key":"3870_CR20","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1017\/S0007114519002769","volume":"123","author":"M Dorosti","year":"2020","unstructured":"Dorosti M et al (2020) Whole-grain consumption and its effects on hepatic steatosis and liver enzymes in patients with non-alcoholic fatty liver disease: a randomised controlled clinical trial. Br J Nutr 123(3):328\u2013336","journal-title":"Br J Nutr"},{"issue":"1","key":"3870_CR21","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s12937-024-00911-x","volume":"23","author":"S Ebrahimpour-Koujan","year":"2024","unstructured":"Ebrahimpour-Koujan S et al (2024) Effects of vitamin D supplementation on liver fibrogenic factors, vitamin D receptor and liver fibrogenic MicroRNAs in metabolic dysfunction-associated steatotic liver disease (MASLD) patients: an exploratory randomized clinical trial. Nutr J 23(1):24","journal-title":"Nutr J"},{"issue":"11","key":"3870_CR22","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1111\/dom.14129","volume":"22","author":"V Lukenda Zanko","year":"2020","unstructured":"Lukenda Zanko V et al (2020) Vitamin D for treatment of non-alcoholic fatty liver disease detected by transient elastography: a randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab 22(11):2097\u20132106","journal-title":"Diabetes Obes Metab"},{"key":"3870_CR23","doi-asserted-by":"crossref","unstructured":"El-Kady RR et al (2022) Nicotinamide supplementation in diabetic nonalcoholic fatty liver disease patients: randomized controlled trial. Therapeutic Adv Chronic Disease, 13","DOI":"10.1177\/20406223221077958"},{"issue":"4","key":"3870_CR24","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1080\/13813455.2021.1890128","volume":"129","author":"N Garousi","year":"2023","unstructured":"Garousi N et al (2023) Effects of lacto-ovo-vegetarian diet vs. standard-weight-loss diet on obese and overweight adults with non-alcoholic fatty liver disease: a randomised clinical trial. Arch Physiol Biochem 129(4):975\u2013983","journal-title":"Arch Physiol Biochem"},{"issue":"8","key":"3870_CR25","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1080\/09637486.2020.1746957","volume":"71","author":"R Hormoznejad","year":"2020","unstructured":"Hormoznejad R et al (2020) Combined cranberry supplementation and weight loss diet in non-alcoholic fatty liver disease: a double-blind placebo-controlled randomized clinical trial. Int J Food Sci Nutr 71(8):991\u20131000","journal-title":"Int J Food Sci Nutr"},{"issue":"7","key":"3870_CR26","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1038\/s41430-022-01081-x","volume":"76","author":"B Khodami","year":"2022","unstructured":"Khodami B et al (2022) Effects of a low free sugar diet on the management of nonalcoholic fatty liver disease: a randomized clinical trial. Eur J Clin Nutr 76(7):987\u2013994","journal-title":"Eur J Clin Nutr"},{"key":"3870_CR27","doi-asserted-by":"crossref","unstructured":"Amirkhizi F et al (2018) Effects of alpha-lipoic acid supplementation on oxidative stress status in patients with nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled clinical trial. Iran Red Crescent Med J, 20(9)","DOI":"10.5812\/ircmj.67615"},{"issue":"2","key":"3870_CR28","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1111\/jcpt.12784","volume":"44","author":"S Hosseinpour-Arjmand","year":"2019","unstructured":"Hosseinpour-Arjmand S, Amirkhizi F, Ebrahimi-Mameghani M (2019) The effect of alpha-lipoic acid on inflammatory markers and body composition in obese patients with non-alcoholic fatty liver disease: a randomized, double-blind, placebo-controlled trial. J Clin Pharm Ther 44(2):258\u2013267","journal-title":"J Clin Pharm Ther"},{"issue":"8","key":"3870_CR29","doi-asserted-by":"publisher","first-page":"4941","DOI":"10.1039\/C9FO00449A","volume":"10","author":"A Rahmanabadi","year":"2019","unstructured":"Rahmanabadi A et al (2019) Oral \u03b1-lipoic acid supplementation in patients with non-alcoholic fatty liver disease: effects on adipokines and liver histology features. Food Funct 10(8):4941\u20134952","journal-title":"Food Funct"},{"issue":"1","key":"3870_CR30","doi-asserted-by":"publisher","first-page":"77","DOI":"10.34172\/hpp.2023.10","volume":"13","author":"T Badali","year":"2023","unstructured":"Badali T et al (2023) The effect of DASH diet on atherogenic indices, pro-oxidant-antioxidant balance, and liver steatosis in obese adults with non-alcoholic fatty liver disease: a double-blind controlled randomized clinical trial. Health Promotion Perspect 13(1):77\u201387","journal-title":"Health Promotion Perspect"},{"issue":"1","key":"3870_CR31","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s12986-023-00733-4","volume":"20","author":"F Rooholahzadegan","year":"2023","unstructured":"Rooholahzadegan F et al (2023) The effect of DASH diet on glycemic response, meta-inflammation and serum LPS in obese patients with NAFLD: a double-blind controlled randomized clinical trial. Nutr Metabolism 20(1):11","journal-title":"Nutr Metabolism"},{"issue":"1","key":"3870_CR32","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s00394-023-03221-w","volume":"63","author":"AA Sangouni","year":"2024","unstructured":"Sangouni AA et al (2024) Dietary approaches to stop hypertension (DASH) diet improves hepatic fibrosis, steatosis and liver enzymes in patients with non-alcoholic fatty liver disease: a randomized controlled trial. Eur J Nutr 63(1):95\u2013105","journal-title":"Eur J Nutr"},{"issue":"1","key":"3870_CR33","doi-asserted-by":"publisher","first-page":"5688","DOI":"10.1038\/s41598-019-42059-3","volume":"9","author":"SB Ahn","year":"2019","unstructured":"Ahn SB et al (2019) Randomized, double-blind, placebo-controlled study of a multispecies probiotic mixture in nonalcoholic fatty liver disease. Sci Rep 9(1):5688","journal-title":"Sci Rep"},{"key":"3870_CR34","doi-asserted-by":"crossref","unstructured":"Ayob N et al (2023) The effects of probiotics on small intestinal microbiota composition, inflammatory cytokines and intestinal permeability in patients with non-alcoholic fatty liver disease. Biomedicines, 11(2)","DOI":"10.3390\/biomedicines11020640"},{"issue":"8","key":"3870_CR35","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1093\/jn\/nxy088","volume":"148","author":"F Bakhshimoghaddam","year":"2018","unstructured":"Bakhshimoghaddam F et al (2018) Daily consumption of synbiotic yogurt decreases liver steatosis in patients with nonalcoholic fatty liver disease: a randomized controlled clinical trial. J Nutr 148(8):1276\u20131284","journal-title":"J Nutr"},{"issue":"10","key":"3870_CR36","doi-asserted-by":"publisher","first-page":"3611","DOI":"10.1111\/1750-3841.15367","volume":"85","author":"V Behrouz","year":"2020","unstructured":"Behrouz V et al (2020) Effects of probiotic and prebiotic supplementation on metabolic parameters, liver aminotransferases, and systemic inflammation in nonalcoholic fatty liver disease: A randomized clinical trial. J Food Sci 85(10):3611\u20133617","journal-title":"J Food Sci"},{"issue":"4","key":"3870_CR37","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1007\/s00394-018-1721-2","volume":"58","author":"MR Bomhof","year":"2019","unstructured":"Bomhof MR et al (2019) Histological improvement of non-alcoholic steatohepatitis with a prebiotic: a pilot clinical trial. Eur J Nutr 58(4):1735\u20131745","journal-title":"Eur J Nutr"},{"issue":"32","key":"3870_CR38","doi-asserted-by":"publisher","first-page":"e21464","DOI":"10.1097\/MD.0000000000021464","volume":"99","author":"GS Cai","year":"2020","unstructured":"Cai GS, Su H, Zhang J (2020) Protective effect of probiotics in patients with non-alcoholic fatty liver disease. Med (Baltim) 99(32):e21464","journal-title":"Med (Baltim)"},{"key":"3870_CR39","doi-asserted-by":"publisher","first-page":"846873","DOI":"10.3389\/fnut.2022.846873","volume":"9","author":"G Derosa","year":"2022","unstructured":"Derosa G et al (2022) Probiotic therapy with VSL#3\u00ae in patients with NAFLD: a randomized clinical trial. Front Nutr 9:846873","journal-title":"Front Nutr"},{"issue":"1","key":"3870_CR40","doi-asserted-by":"publisher","first-page":"e000315","DOI":"10.1136\/bmjgast-2019-000315","volume":"6","author":"A Duseja","year":"2019","unstructured":"Duseja A et al (2019) High potency multistrain probiotic improves liver histology in non-alcoholic fatty liver disease (NAFLD): a randomised, double-blind, proof of concept study. BMJ Open Gastroenterol 6(1):e000315","journal-title":"BMJ Open Gastroenterol"},{"key":"3870_CR41","doi-asserted-by":"crossref","unstructured":"Kobyliak N et al (2018) A multi-strain probiotic reduces the fatty liver index, cytokines and aminotransferase levels in NAFLD patients: evidence from a randomized clinical trial","DOI":"10.15403\/jgld.2014.1121.271.kby"},{"issue":"6","key":"3870_CR42","first-page":"76","volume":"14","author":"MHM Nor","year":"2020","unstructured":"Nor MHM et al (2020) The effect of probiotics on the clinical outcomes of patients with non-alcoholic fatty liver disease: preliminary results from A Randomized, Double-Blind, Placebo-Controlled pilot study. Gut Liver 14(6):76","journal-title":"Gut Liver"},{"issue":"6","key":"3870_CR43","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1053\/j.gastro.2020.01.031","volume":"158","author":"E Scorletti","year":"2020","unstructured":"Scorletti E et al (2020) Synbiotics alter fecal microbiomes, but not liver fat or fibrosis, in a randomized trial of patients with nonalcoholic fatty liver disease. Gastroenterology 158(6):1597\u20131610e7","journal-title":"Gastroenterology"},{"issue":"9","key":"3870_CR44","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1038\/s41430-018-0386-5","volume":"73","author":"S Chashmniam","year":"2019","unstructured":"Chashmniam S et al (2019) A pilot study of the effect of phospholipid Curcumin on serum metabolomic profile in patients with non-alcoholic fatty liver disease: a randomized, double-blind, placebo-controlled trial. Eur J Clin Nutr 73(9):1224\u20131235","journal-title":"Eur J Clin Nutr"},{"issue":"3","key":"3870_CR45","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1038\/s41430-018-0382-9","volume":"73","author":"S Saadati","year":"2019","unstructured":"Saadati S et al (2019) The effects of Curcumin supplementation on liver enzymes, lipid profile, glucose homeostasis, and hepatic steatosis and fibrosis in patients with non-alcoholic fatty liver disease. Eur J Clin Nutr 73(3):441\u2013449","journal-title":"Eur J Clin Nutr"},{"issue":"5\u20136","key":"3870_CR46","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1024\/0300-9831\/a000568","volume":"89","author":"A Ghaffari","year":"2019","unstructured":"Ghaffari A et al (2019) Turmeric and chicory seed have beneficial effects on obesity markers and lipid profile in non-alcoholic fatty liver disease (NAFLD). International journal for vitamin and nutrition research. Internationale Zeitschrift fur Vitamin- und Ernahrungsforschung. J Int De Vitaminologie Et De Nutr 89(5\u20136):293\u2013302","journal-title":"J Int De Vitaminologie Et De Nutr"},{"key":"3870_CR47","first-page":"2217","volume-title":"Efficacy of Curcumin plus Piperine co-supplementation in moderate-to-high hepatic steatosis: a double-blind, randomized, placebo-controlled clinical trial","author":"S Sharifi","year":"2023","unstructured":"Sharifi S et al (2023) Efficacy of Curcumin plus Piperine co-supplementation in moderate-to-high hepatic steatosis: a double-blind, randomized, placebo-controlled clinical trial, vol 37. PTR, Phytotherapy research, pp 2217\u20132229. 6"},{"issue":"11","key":"3870_CR48","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.1111\/dom.14804","volume":"24","author":"PH Hellmann","year":"2022","unstructured":"Hellmann PH et al (2022) The effect of Curcumin on hepatic fat content in individuals with obesity. Diabetes Obes Metabolism 24(11):2192\u20132202","journal-title":"Diabetes Obes Metabolism"},{"issue":"1","key":"3870_CR49","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1007\/s40200-023-01375-2","volume":"23","author":"M Alizadeh","year":"2024","unstructured":"Alizadeh M et al (2024) The effects of meal patterns on liver steatosis, fibrosis, and biochemical factors in patients with nonalcoholic fatty liver disease: a randomized controlled clinical trial. J Diabetes Metab Disord 23(1):987\u2013997","journal-title":"J Diabetes Metab Disord"},{"issue":"1","key":"3870_CR50","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.cmet.2022.12.001","volume":"35","author":"M Ezpeleta","year":"2023","unstructured":"Ezpeleta M et al (2023) Effect of alternate day fasting combined with aerobic exercise on non-alcoholic fatty liver disease: a randomized controlled trial. Cell Metabol 35(1):56\u201370e3","journal-title":"Cell Metabol"},{"key":"3870_CR51","doi-asserted-by":"crossref","unstructured":"Holmer M et al (2021) Treatment of NAFLD with intermittent calorie restriction or low-carb high-fat diet \u2013 a randomised controlled trial. JHEP Rep, 3(3)","DOI":"10.1016\/j.jhepr.2021.100256"},{"key":"3870_CR52","doi-asserted-by":"crossref","first-page":"17","DOI":"10.5009\/gnl16510","volume":"12","author":"MI Johari","year":"2018","unstructured":"Johari MI et al (2018) A randomized controlled trial on the effectiveness and adherence of modified alternate-day calorie restriction in improving activity of nonalcoholic fatty liver disease. Gut Liver 12:17","journal-title":"Gut Liver"},{"key":"3870_CR53","doi-asserted-by":"crossref","unstructured":"Johari MI et al (2019) A randomised controlled trial on the effectiveness and adherence of modified alternate-day calorie restriction in improving activity of non-alcoholic fatty liver disease. Sci Rep, 9","DOI":"10.1038\/s41598-019-47763-8"},{"key":"3870_CR54","doi-asserted-by":"publisher","first-page":"948655","DOI":"10.3389\/fnut.2022.948655","volume":"9","author":"H Kord Varkaneh","year":"2022","unstructured":"Kord Varkaneh H et al (2022) Effects of the 5: 2 intermittent fasting diet on non-alcoholic fatty liver disease: a randomized controlled trial. Front Nutr 9:948655","journal-title":"Front Nutr"},{"key":"3870_CR55","doi-asserted-by":"publisher","first-page":"111847","DOI":"10.1016\/j.nut.2022.111847","volume":"105","author":"H Kord-Varkaneh","year":"2023","unstructured":"Kord-Varkaneh H et al (2023) Effects of time-restricted feeding (16\/8) combined with a low-sugar diet on the management of non-alcoholic fatty liver disease: A randomized controlled trial. Nutrition 105:111847","journal-title":"Nutrition"},{"issue":"1","key":"3870_CR56","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1186\/s13063-023-07444-4","volume":"24","author":"HA Lee","year":"2023","unstructured":"Lee HA et al (2023) Effect of 12-week intermittent calorie restriction compared to standard of care in patients with nonalcoholic fatty liver disease: a randomized controlled trial. Trials 24(1):490","journal-title":"Trials"},{"key":"3870_CR57","doi-asserted-by":"crossref","unstructured":"Wei XY et al (2023) Effects of time-restricted eating on nonalcoholic fatty liver disease: the TREATY-FLD randomized clinical trial. Jama Netw Open, 6(3)","DOI":"10.1001\/jamanetworkopen.2023.3513"},{"issue":"3","key":"3870_CR58","first-page":"483","volume":"29","author":"J Chen","year":"2020","unstructured":"Chen J et al (2020) Impact of a low-carbohydrate and high-fiber diet on nonalcoholic fatty liver disease. Asia Pac J Clin Nutr 29(3):483\u2013490","journal-title":"Asia Pac J Clin Nutr"},{"issue":"1","key":"3870_CR59","doi-asserted-by":"publisher","first-page":"10","DOI":"10.7326\/M22-1787","volume":"176","author":"CD Hansen","year":"2023","unstructured":"Hansen CD et al (2023) Effect of calorie-unrestricted low-carbohydrate,high-fat diet versus high-carbohydrate, low-fat diet on type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial. Ann Intern Med 176(1):10\u201321","journal-title":"Ann Intern Med"},{"key":"3870_CR60","first-page":"S602","volume":"76","author":"S Chirapongsathorn","year":"2022","unstructured":"Chirapongsathorn S et al (2022) Effect of a ketogenic diet on nonalcoholic fatty liver disease (NAFLD) progression: a randomized controlled trial. Hepatology (Baltimore MD) 76:S602","journal-title":"Hepatology (Baltimore MD)"},{"issue":"3","key":"3870_CR61","doi-asserted-by":"publisher","first-page":"E22","DOI":"10.1111\/hepr.12918","volume":"48","author":"EC Jang","year":"2018","unstructured":"Jang EC et al (2018) Comparison of efficacy of low-carbohydrate and low-fat diet education programs in non-alcoholic fatty liver disease: A randomized controlled study. Hepatol Res 48(3):E22\u2013e29","journal-title":"Hepatol Res"},{"issue":"3","key":"3870_CR62","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1111\/jog.14650","volume":"47","author":"J Li","year":"2021","unstructured":"Li J et al (2021) Ketogenic diet in women with polycystic ovary syndrome and liver dysfunction who are obese: a randomized, open-label, parallel-group, controlled pilot trial. J Obstet Gynaecol Res 47(3):1145\u20131152","journal-title":"J Obstet Gynaecol Res"},{"issue":"1","key":"3870_CR63","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s12937-024-00968-8","volume":"23","author":"Z Liu","year":"2024","unstructured":"Liu Z et al (2024) A comprehensive approach to lifestyle intervention based on a calorie-restricted diet ameliorates liver fat in overweight\/obese patients with NAFLD: a multicenter randomized controlled trial in China. Nutr J 23(1):64","journal-title":"Nutr J"},{"key":"3870_CR64","doi-asserted-by":"crossref","unstructured":"Marin-Alejandre BA et al (2019) The metabolic and hepatic impact of two personalized dietary strategies in subjects with obesity and nonalcoholic fatty liver disease: the fatty liver in obesity (FLiO) randomized controlled trial. Nutrients, 11(10)","DOI":"10.3390\/nu11102543"},{"issue":"7","key":"3870_CR65","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1111\/liv.14818","volume":"41","author":"BA Marin-Alejandre","year":"2021","unstructured":"Marin-Alejandre BA et al (2021) Effects of two personalized dietary strategies during a 2-year intervention in subjects with nonalcoholic fatty liver disease: a randomized trial. Liver Int 41(7):1532\u20131544","journal-title":"Liver Int"},{"key":"3870_CR66","doi-asserted-by":"crossref","unstructured":"Abbate M et al (2021) Energy expenditure improved risk factors associated with renal function loss in NAFLD and MetS patients. Nutrients 13(2)","DOI":"10.3390\/nu13020629"},{"key":"3870_CR67","doi-asserted-by":"crossref","unstructured":"Chiurazzi M et al (2022) The synergic effect of a nutraceutical supplementation associated to a mediterranean hypocaloric diet in a population of overweight\/obese adults with NAFLD. Nutrients 14(22)","DOI":"10.3390\/nu14224750"},{"issue":"3","key":"3870_CR68","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1016\/j.ajcnut.2023.11.013","volume":"119","author":"YC Chooi","year":"2024","unstructured":"Chooi YC et al (2024) Effect of an asian-adapted mediterranean diet and Pentadecanoic acid on fatty liver disease: the TANGO randomized controlled trial. Am J Clin Nutr 119(3):788\u2013799","journal-title":"Am J Clin Nutr"},{"key":"3870_CR69","doi-asserted-by":"crossref","unstructured":"Curci R et al (2023) Lifestyle modification: evaluation of the effects of physical activity and low-glycemic-index mediterranean diet on fibrosis score. Nutrients 15(16)","DOI":"10.3390\/nu15163520"},{"key":"3870_CR70","doi-asserted-by":"publisher","first-page":"1181706","DOI":"10.3389\/fnut.2023.1181706","volume":"10","author":"HL Fateh","year":"2023","unstructured":"Fateh HL et al (2023) Comparing effects of beetroot juice and mediterranean diet on liver enzymes and sonographic appearance in patients with non-alcoholic fatty liver disease: a randomized control trials. Front Nutr 10:1181706","journal-title":"Front Nutr"},{"issue":"SUPPL 3","key":"3870_CR71","first-page":"160","volume":"36","author":"ES George","year":"2021","unstructured":"George ES et al (2021) Impact of a mediterranean diet on hepatic and metabolic outcomes in non-alcoholic fatty liver disease: the MEDINA randomized controlled trial. J Gastroenterol Hepatol 36(SUPPL 3):160","journal-title":"J Gastroenterol Hepatol"},{"issue":"2","key":"3870_CR72","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1017\/S000711451800137X","volume":"120","author":"CN Katsagoni","year":"2018","unstructured":"Katsagoni CN et al (2018) Improvements in clinical characteristics of patients with non-alcoholic fatty liver disease, after an intervention based on the mediterranean lifestyle: a randomised controlled clinical trial. Br J Nutr 120(2):164\u2013175","journal-title":"Br J Nutr"},{"key":"3870_CR73","doi-asserted-by":"crossref","unstructured":"Montemayor S et al (2022) Effect of dietary and lifestyle interventions on the amelioration of NAFLD in patients with metabolic syndrome: the FLIPAN study. Nutrients 14(11)","DOI":"10.3390\/nu14112223"},{"issue":"5","key":"3870_CR74","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1002\/hep.30076","volume":"68","author":"C Properzi","year":"2018","unstructured":"Properzi C et al (2018) Ad libitum mediterranean and low-fat diets both significantly reduce hepatic steatosis: a randomized controlled trial. Hepatology (Baltimore MD) 68(5):1741\u20131754","journal-title":"Hepatology (Baltimore MD)"},{"key":"3870_CR75","doi-asserted-by":"crossref","unstructured":"Quetglas-Llabr\u00e9s MM et al (2023) Mediterranean diet improves plasma biomarkers related to oxidative stress and inflammatory process in patients with non-alcoholic fatty liver disease. Antioxidants 12(4)","DOI":"10.3390\/antiox12040833"},{"key":"3870_CR76","doi-asserted-by":"crossref","unstructured":"Ristic-Medic D et al (2020) Calorie-restricted mediterranean and low-fat diets affect fatty acid status in individuals with nonalcoholic fatty liver disease. Nutrients 13(1)","DOI":"10.3390\/nu13010015"},{"issue":"7","key":"3870_CR77","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1016\/j.clnu.2024.05.042","volume":"43","author":"P Mogna-Pel\u00e1ez","year":"2024","unstructured":"Mogna-Pel\u00e1ez P et al (2024) Inflammatory markers as diagnostic and precision nutrition tools for metabolic dysfunction-associated steatotic liver disease: results from the fatty liver in obesity trial. Clin Nutr 43(7):1770\u20131781","journal-title":"Clin Nutr"},{"issue":"16","key":"3870_CR78","doi-asserted-by":"publisher","first-page":"e016334","DOI":"10.1161\/JAHA.119.016334","volume":"9","author":"J Climax","year":"2020","unstructured":"Climax J et al (2020) Effects of epeleuton, a novel synthetic second-generation n-3 fatty acid, on non-alcoholic fatty liver disease, triglycerides, glycemic control, and cardiometabolic and inflammatory markers. J Am Heart Association 9(16):e016334","journal-title":"J Am Heart Association"},{"issue":"9","key":"3870_CR79","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1017\/S0007114520000318","volume":"123","author":"S Rezaei","year":"2020","unstructured":"Rezaei S et al (2020) Flaxseed oil in the context of a weight loss programme ameliorates fatty liver grade in patients with non-alcoholic fatty liver disease: a randomised double-blind controlled trial. Br J Nutr 123(9):994\u20131002","journal-title":"Br J Nutr"},{"key":"3870_CR80","doi-asserted-by":"crossref","unstructured":"Shojasaadat F et al (2019) A randomized controlled trial comparing effects of a low-energy diet with n-3 polyunsaturated fatty acid supplementation in patients with non-alcoholic fatty liver disease. J Res Med Sci 24","DOI":"10.4103\/jrms.JRMS_282_18"},{"issue":"6","key":"3870_CR81","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1002\/hep4.1906","volume":"6","author":"V \u0160m\u00edd","year":"2022","unstructured":"\u0160m\u00edd V et al (2022) Effect of omega-3 polyunsaturated fatty acids on lipid metabolism in patients with metabolic syndrome and NAFLD. Hepatol Commun 6(6):1336\u20131349","journal-title":"Hepatol Commun"},{"issue":"1","key":"3870_CR82","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/s41430-020-0679-3","volume":"75","author":"Z Yari","year":"2021","unstructured":"Yari Z et al (2021) The efficacy of flaxseed and hesperidin on non-alcoholic fatty liver disease: an open-labeled randomized controlled trial. Eur J Clin Nutr 75(1):99\u2013111","journal-title":"Eur J Clin Nutr"},{"issue":"6","key":"3870_CR83","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa2309000","volume":"390","author":"SA Harrison","year":"2024","unstructured":"Harrison SA et al (2024) A phase 3, randomized, controlled trial of Resmetirom in NASH with liver fibrosis. N Engl J Med 390(6):497\u2013509","journal-title":"N Engl J Med"},{"issue":"7","key":"3870_CR84","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1210\/clinem\/dgad036","volume":"108","author":"J Liu","year":"2023","unstructured":"Liu J, Yi P, Liu F (2023) The effect of early time-restricted eating vs later time-restricted eating on weight loss and metabolic health. J Clin Endocrinol Metab 108(7):1824\u20131834","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"3870_CR85","doi-asserted-by":"publisher","first-page":"3428","DOI":"10.1210\/clinem\/dgac570","volume":"107","author":"L Liu","year":"2022","unstructured":"Liu L et al (2022) Metabolic efficacy of time-restricted eating in adults: a systematic review and meta-analysis of randomized controlled trials. J Clin Endocrinol Metab 107(12):3428\u20133441","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"3870_CR86","doi-asserted-by":"publisher","first-page":"354","DOI":"10.4330\/wjc.v15.i7.354","volume":"15","author":"M Kamarul Zaman","year":"2023","unstructured":"Kamarul Zaman M et al (2023) Effects of time-restricted eating with different eating duration on anthropometrics and cardiometabolic health: A systematic review and meta-analysis. World J Cardiol 15(7):354\u2013374","journal-title":"World J Cardiol"},{"key":"3870_CR87","doi-asserted-by":"publisher","first-page":"1079250","DOI":"10.3389\/fnut.2023.1079250","volume":"10","author":"W Chen","year":"2023","unstructured":"Chen W et al (2023) Health effects of the time-restricted eating in adults with obesity: A systematic review and meta-analysis. Front Nutr 10:1079250","journal-title":"Front Nutr"},{"issue":"1","key":"3870_CR88","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.jhep.2021.02.027","volume":"75","author":"B Geidl-Flueck","year":"2021","unstructured":"Geidl-Flueck B et al (2021) Fructose- and sucrose- but not glucose-sweetened beverages promote hepatic de Novo lipogenesis: a randomized controlled trial. J Hepatol 75(1):46\u201354","journal-title":"J Hepatol"},{"key":"3870_CR89","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1146\/annurev-nutr-062220-025831","volume":"42","author":"S Jung","year":"2022","unstructured":"Jung S et al (2022) Dietary Fructose and Fructose-induced pathologies. Annu Rev Nutr 42:45\u201366","journal-title":"Annu Rev Nutr"},{"issue":"5","key":"3870_CR90","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1016\/j.clnu.2018.09.022","volume":"38","author":"J Ahn","year":"2019","unstructured":"Ahn J et al (2019) Critical appraisal for low-carbohydrate diet in nonalcoholic fatty liver disease: review and meta-analyses. Clin Nutr 38(5):2023\u20132030","journal-title":"Clin Nutr"},{"key":"3870_CR91","doi-asserted-by":"crossref","unstructured":"Moradi S et al The dietary pattern concerning non-alcoholic fatty liver: an umbrella review and meta-analyses of observational studies and intervention trials. J Kermanshah Univ Med Sci. 28(3)","DOI":"10.5812\/jkums-142759"},{"issue":"9","key":"3870_CR92","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1016\/j.clnu.2022.06.037","volume":"41","author":"L Haigh","year":"2022","unstructured":"Haigh L et al (2022) The effectiveness and acceptability of mediterranean diet and calorie restriction in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis. Clin Nutr 41(9):1913\u20131931","journal-title":"Clin Nutr"},{"issue":"10","key":"3870_CR93","doi-asserted-by":"publisher","first-page":"2250","DOI":"10.3390\/nu15102250","volume":"15","author":"C Del Bo\u2019","year":"2023","unstructured":"Del Bo\u2019 C et al (2023) Does the mediterranean diet have any effect on lipid profile, central obesity and liver enzymes in non-alcoholic fatty liver disease (NAFLD) subjects? A systematic review and Meta-analysis of randomized control trials. Nutrients 15(10):2250","journal-title":"Nutrients"},{"key":"3870_CR94","doi-asserted-by":"crossref","unstructured":"Kawaguchi T et al (2021) Effects of mediterranean diet in patients with nonalcoholic fatty liver disease: a systematic review, meta-analysis, and meta-regression analysis of randomized controlled trials. Seminars in liver disease. Thieme Medical Publishers, Inc.","DOI":"10.1055\/s-0041-1723751"},{"key":"3870_CR95","doi-asserted-by":"crossref","unstructured":"Mirabelli M et al (2020) Mediterranean diet nutrients to turn the tide against insulin resistance and related diseases. Nutrients 12(4)","DOI":"10.3390\/nu12041066"},{"key":"3870_CR96","doi-asserted-by":"crossref","unstructured":"Lu W et al (2016) Effects of omega-3 fatty acid in nonalcoholic fatty liver disease: a meta-analysis. Gastroenterol Res Pract, 2016: 1459790","DOI":"10.1155\/2016\/1459790"},{"issue":"4","key":"3870_CR97","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1016\/j.jhep.2011.08.018","volume":"56","author":"HM Parker","year":"2012","unstructured":"Parker HM et al (2012) Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Hepatol 56(4):944\u2013951","journal-title":"J Hepatol"},{"issue":"10","key":"3870_CR98","doi-asserted-by":"publisher","first-page":"e0162368","DOI":"10.1371\/journal.pone.0162368","volume":"11","author":"XX He","year":"2016","unstructured":"He XX et al (2016) Effectiveness of omega-3 polyunsaturated fatty acids in non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials. PLoS ONE 11(10):e0162368","journal-title":"PLoS ONE"},{"issue":"37","key":"3870_CR99","doi-asserted-by":"publisher","first-page":"e12271","DOI":"10.1097\/MD.0000000000012271","volume":"97","author":"JH Yan","year":"2018","unstructured":"Yan JH et al (2018) Omega-3 polyunsaturated fatty acid supplementation and non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials. Med (Baltim) 97(37):e12271","journal-title":"Med (Baltim)"},{"issue":"5","key":"3870_CR100","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.amjms.2024.01.022","volume":"367","author":"S Condon","year":"2024","unstructured":"Condon S et al (2024) ALT poorly predicts nonalcoholic fatty liver disease (NAFLD) and liver fibrosis as determined by vibration-controlled transient elastography in adult National health and nutrition examination survey 2017\u20132018. Am J Med Sci 367(5):310\u2013322","journal-title":"Am J Med Sci"},{"issue":"2","key":"3870_CR101","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1056\/NEJMoa1212914","volume":"369","author":"RR Wing","year":"2013","unstructured":"Wing RR et al (2013) Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med 369(2):145\u2013154","journal-title":"N Engl J Med"},{"issue":"10215","key":"3870_CR102","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","volume":"394","author":"ZM Younossi","year":"2019","unstructured":"Younossi ZM et al (2019) Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 394(10215):2184\u20132196","journal-title":"Lancet"}],"container-title":["European Journal of Nutrition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00394-025-03870-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00394-025-03870-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00394-025-03870-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:16:05Z","timestamp":1781633765000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00394-025-03870-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,14]]},"references-count":102,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["3870"],"URL":"https:\/\/doi.org\/10.1007\/s00394-025-03870-z","relation":{},"ISSN":["1436-6207","1436-6215"],"issn-type":[{"value":"1436-6207","type":"print"},{"value":"1436-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,14]]},"assertion":[{"value":"16 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MM declares consultant honorary from Atheneum, Boehringer Ingelheim, Ipsen; speaker honorarium from AbbVie, Astra Zeneca, Cogitando, Coliquio, Daiichi Sankyo, Gilead Sciences, GSK, Ipsen, Novo Nordisk, StreamedUp. JMS declares consultant honorary from Akero, Alentis, Alexion, Altimmune, Astra Zeneca, 89Bio, Boehringer Ingelheim, Boston Pharmaceuticals, Gilead Sciences, GSK, Ipsen, Inventiva Pharma, Madrigal Pharmaceuticals, Kr\u00edya Therapeutics, Eli Lilly, eTherapeutics, Merck, MSD Sharp & Dohme GmbH, Novo Nordisk, Roche; speaker honorarium from AbbVie, Boehringer Ingelheim, Gilead Sciences, Ipsen, Lilly, Madrigal Pharmaceuticals, MSD, Novo Nordisk. Stockholder options: Hepta Bio.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"58"}}